絞り込み

16242

広告

Phase II study of short-course CHOP-rituximab followed by (90)y ibritumomab tiuxetan as first-line treatment for follicular lymphoma: Analysis of FcγR variants.

著者 Mehta DR , Reichert V , Lewis ME , Lenzner DE , Kant JA , Jacobs SA
J Clin Oncol.2011 May 20 ; 29(15_suppl):e18526.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (6view , 0users)
  • このエントリーをはてなブックマークに追加

Miscellaneous

e18526 Background: Independent studies have suggested follicular lymphoma (FL) patients who are homozygous for 158V and 131H alleles in the FcγRIIIa and FcγRIIa genes respectively, achieve higher response rates with rituximab monotherapy. We previously reported complete response rate (CR) of 89% in 60 untreated patients with stage II-IV symptomatic or bulky FL who received short-course CHOP-rituximab (R) x 3 cycles followed by ibritumomab tiuxetan (IT) and extended R as first-line treatment (SA Jacobs, et al. Clin Cancer Res 2008) and presented follow-up results (DR Mehta, et al. ASCO 2010). This abstract reviews a subgroup of 32 such patients genotyped for these polymorphisms.
PMID: 28023272 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード